广东省“卓越青年”团队负责人、广州市医用纳米材料重点实验室主任、中山大学孙逸仙纪念医院基础与转化医学研究中心副主任、科研科副科长，入选海外引进高层次人才计划、广东省“珠江人才计划”引进高层次人才、广东省 “杰出青年医学人才”，担任中国生物物理学会代谢生物学分会青年理事及副秘书长、 中国老年医学学会肿瘤基础及转化研究专委会委员、广东省青科协常务理事、广东省青科协生物与医药科学专委会副主任、广东省抗癌协会纳米肿瘤学专业委员会候任主委、广东省抗癌协会肿瘤转移专业委员会委员；主要从事肿瘤恶性进展作用机制及靶向干预研究工作。目前在Cell, PNAS, Advanced Science, Cancer Research, Advanced Materials, ACS Nano, Nano Letters, Small, Biomaterials等学术期刊发表论文140余篇，论文他引8200余次（5篇研究论文入选ESI高被引论文），H-index 52；授权/受理权利18项（中国专利10项，美国专利4项，国际专利4项）。研究成果被Cell, Nature Reviews Drug Discovery, SciTechDaily, PNAS Feature News, Cell Therapy News, Prostate Cell News, Pharmacy Choice以及Gene Therapy Net等专题报道。现担任Advanced Science, Nature Communications, ACS Nano, Biomaterials等30多种学术期刊审稿人。

联系方式：xuxiaod5@mail.sysu.edu.cn

近5年代表性论文

1. Qiyi Zhao,# Jiayu Liu,# Hong Deng,# Ruiying Ma,# Jian-You Liao, Huixin Liang, Jingxiong Hu, Jiaqian Li, Zhiyong Guo, Junchao Cai, Xiaoding Xu,* Zhiliang Gao,* Shicheng Su.* Targeting mitochondria-located circRNA SCAR alleviates NASH via reducing mROS output. Cell 2020, 183, 76-93. (IF 64.5; 研究成果入选国际寡核苷酸治疗协会2020年9月的月度文章, 同时被Nature Review Drug Discovery和Cell专题评述推荐)
2. Senlin Li,# Lei Xu,# Guo Wu, Ziqi Huang, Linzhuo Huang, Fengqian Zhang, Chunfang Wei, Qian Shen, Rong Li, Lei Zhang,* Xiaoding Xu.* Remodeling serine synthesis and metabolism via nanoparticles (NPs)-mediated CFL1 silencing to enhance the sensitivity of hepatocellular carcinoma to sorafenib. Advanced Science 2023, 10, 2207118. (IF 15.1)
3. Rui Xu,# Linzhuo Huang,# Jiayu Liu,# Yuxuan Zhang, Ya Xu, Rong Li, Shicheng Su, Xiaoding Xu.* Remodeling of mitochondrial metabolism by mitochondria-targeted RNAi nanoplatform for effective cancer therapy. Small 2024, 20, 2305923. (IF 13.3)
4. Rui Xu,# Xiangya Liu,# Yuxuan Zhang,# Guo Wu, Linzhuo Huang, Rong Li,* Xiaoding Xu.* Antibody-decorated nanoplatform to reprogram macrophage and block immune checkpoint LSECtin for effective cancer immunotherapy. Nano Letters 2024, 24, 8723-8731. (IF 10.8)
5. Zhihui Dong,# Zhuoshan Huang,# SenlinLi, YingWang, YandanYao, XianzhuYang, Xiaoding Xu.* Nanoparticles (NPs)-mediated systemic mRNA delivery to reverse trastuzumab resistance for effective breast cancer therapy. Acta Pharmaceutica Sinica B 2023, 13, 955-966. (IF 14.5)
6. Chunfang Wei,# Ya Xu,# Qian Shen, Rong Li, Xiaoyun Xiao, Phei Er Saw,* Xiaoding Xu.* Role of long non-coding RNAs in cancer: From subcellular localization to nanoparticle-mediated targeted regulation. Molecular Therapy: Nucleic Acids 2023, 33, 774-793. (IF 8.8; 邀请综述)
7. Shuwen Cao,# Phei Er Saw,# Qian Shen, Rong Li, Yun Liu, Xiaoding Xu.* Reduction-responsive RNAi nanoplatform to reprogram tumor lipid metabolism and repolarize macrophage for combination pancreatic cancer therapy. Biomaterials 2022, 280, 121264. (IF 14.0)
8. Xiwang Yang, Ya Wen, Shaomin Liu, Liqiang Duan, Tongfeng Liu, Zhou Tong, Zhuo Wang, Yinmin Gu, Yibo Xi, Xiaodong Wang, Dingsan Luo, Ruobing Zhang, Yajuan Liu, Yang Wang, Tianyou Cheng, Siyuan Jiang, Xiaofeng Zhu, Xiaohui Yang, Yongbo Pan, Shuwen Cheng, Qinong Ye, Jinfei Chen,* Xiaoding Xu,* Shan Gao.* LCDR regulates the integrity of lysosomal membrane by hnRNP K-stabilized LAPTM5 transcript and promotes cell survival. Proc Natl Acad Sci USA 2022, 119, e2110428119. (IF 11.1; 研究成果被PNAS及SciTechDaily专题评述推荐)
9. Lei Xu,# Rui Xu,# Phei Er Saw, Jun Wu, Si-Xue Cheng, Xiaoding Xu.* Nanoparticle-mediated inhibition of mitochondrial glutaminolysis to amplify oxidative stress for combination cancer therapy. Nano Letters 2021, 21, 7569-7578. (IF 10.8; 研究工作入选期刊月最高阅读20篇论文之一)
10. Phei Er Saw,# Herui Yao,# Chunhao Lin,# Wei Tao, Omid C Farokhzad,* Xiaoding Xu.* Stimuli-responsive polymer-prodrug hybrid nanoplatform for multistage siRNA delivery and combination cancer therapy. Nano Letters 2019, 19, 5967-5974. (IF 10.8; 研究工作入选期刊月最高阅读20篇论文之一)